- Indaptus Therapeutics Inc INDP announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company's Decoy anti-tumor platform.
- Decoy10 demonstrated a 90% reduction of LPS-endotoxin activity and the use of 100% killed, non-pathogenic bacteria.
- Decoy10 inhibited tumor growth and metastasis and induced tumor regressions as a single agent.
- Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
- Regressions were durable and associated with immunological memory-mediated rejection of tumor rechallenge.
- In vivo anti-tumor activity was seen with colorectal, breast, hepatocellular, pancreatic carcinomas, and non-Hodgkin's lymphomas (mouse and human) in preclinical models.
- In December 2022, the company initiated its Phase 1 dose escalation and expansion clinical trial of Decoy20 in patients with advanced solid tumors where currently approved therapies have failed.
- The Phase 1 study has begun with a single dose escalation followed by an expansion with continuous administration of Decoy20.
- Price Action: INDP shares are up 5.08% at $2.59 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in